qli5 therapeutics

Qli5 Therapeutics is a health and wellness startup founded in 2020 with the ambition to revolutionize the field of proteasome inhibitors. The company's mission is encapsulated in its slogan, "Pioneering a breakthrough in proteasome inhibitors with unmatched selectivity and innovative, non-covalent binding properties." Qli5 Therapeutics is dedicated to developing a new class of proteasome inhibitors with high selectivity and unique, non-covalent binding properties.

The company's latest milestone was a significant achievement, securing a €10.00M Series A investment on 07 September 2022. The investment came from a group of prominent investors, including KHAN Technology Transfer Fund, SV Investment, Atinum Partners, and DAOL Investment.

This recent investment not only reflects the confidence of the investor consortium in Qli5's vision and potential but also provides the necessary financial resources to drive the company's research and development efforts forward. Qli5 Therapeutics is well-positioned to make significant strides in developing cutting-edge therapies with the potential to address unmet medical needs in the field of proteasome inhibition.